Study wrapper · #1099
Beyond glycemic control: clinical cardiovascular effects of tirzepatide-a narrative review.
Alawad AO, Merghani TH, Fadelelmoula TE, et al. Therapeutic advances in endocrinology and metabolism. 2026.
DOI: 10.1177/20420188261469947PubMed: 42534427
Editor's note
A narrative review synthesizing the cardiometabolic evidence for tirzepatide across the SURPASS and SURMOUNT programs. Because major adverse cardiovascular event outcomes are still under investigation, the reported cardiovascular benefits remain mechanistic and associative pending dedicated trials.
Plain-language abstract
This narrative review summarizes evidence that tirzepatide, beyond lowering blood sugar, is associated with improvements in blood pressure, lipids, visceral fat, and inflammatory markers relevant to cardiovascular health. Dedicated cardiovascular outcome trials are still ongoing.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026